Keveyis
NDC Package 51672-4177-1

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Keveyis is a medication used to treat a certain inherited condition that causes attacks of muscle weakness or loss of muscle movement that come and go (primary periodic paralysis). Marketed by Taro Pharmaceuticals U.s.a., Inc., this product is identified by NDC 51672-4177 and is authorized under FDA application NDA011366.

Identification & Billing

NDC Package Code
51672-4177-1
Package Description
100 TABLET in 1 BOTTLE
Product Code
51672-4177
11-Digit Billing Format
51672417701
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
100 EA

Clinical Specifications

Proprietary Name
Keveyis
Dosage Form
-
Usage Information
This medication is used to treat a certain inherited condition that causes attacks of muscle weakness or loss of muscle movement that come and go (primary periodic paralysis). Dichlorphenamide belongs to a class of drugs known as carbonic anhydrase inhibitors. It is not known how it works for this condition, but it can decrease the number of attacks of muscle weakness.

Regulatory & Marketing

Labeler Name
Taro Pharmaceuticals U.s.a., Inc.
FDA Application #
NDA011366
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
08-07-2015
End Marketing Date
05-27-2022
Listing Expiration
05-27-2022
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 51672-4177-1 identifies a specific commercial package of 100 tablet in 1 bottle of Keveyis, labeled by Taro Pharmaceuticals U.s.a., Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 100 billable units per package. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Taro Pharmaceuticals U.s.a., Inc. on August 07, 2015. The current certification is valid through May 27, 2022.

What are the primary indications for this medication?

This medication is used to treat a certain inherited condition that causes attacks of muscle weakness or loss of muscle movement that come and go (primary periodic paralysis). Dichlorphenamide belongs to a class of drugs known as carbonic anhydrase inhibitors. It is not known how it works for this condition, but it can decrease the number of attacks of muscle weakness.

How is this Taro Pharmaceuticals U.s.a., Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 51672417701. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
51672-4177-1
11-Digit CMS (5-4-2)
51672-4177-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.